About us Our people Our businesses News and insights Contact us K2 HealthVentures HOME OUR BUSINESSES L1 HEALTH K2 HEALTHVENTURES Formed in 2019, K2 HealthVentures (K2HV) provides life sciences companies at the venture and growth stages with innovative financing solutions. K2HV focuses on flexible debt financing, enabling innovative companies to expand their research programs and minimize equity dilution as they reach key lifecycle milestones and build enterprise value. K2HV can also invest equity capital to align its interests with its venture and public equity investment partners. Driving innovation in life sciences requires ever larger amounts of capital to finance research, development and commercialization. This growing appetite for funding powers the demand for new forms of investment that package risk and returns advantageously for both innovator and investor. The K2HV platform provides an industry team of scientists and financing experts with a permanent source of substantial capital resources to challenge prevailing industry models with creative, adaptive financing solutions. K2HV’s charter commits it to spend a portion of its investment profits to funding globally underserved and underinvested areas in healthcare. K2HV made excellent progress over the past year, making investments in renowned private and public life sciences companies: Evelo Biosciences, a clinical-stage biotechnology company, is developing oral biologics that act on cells in the small intestine with systemic therapeutic effects. A $45m debt financing commitment will help advance a clinical portfolio of oral biologics to treat inflammation and oncology. Metacrine, a clinical-stage biotechnology company, is focused on building a pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. A $50m debt financing commitment supports further development of its best-in-class FXR agonists for treating non-alcoholic steatohepatitis (NASH) and inflammatory bowel disease. Surface Oncology, a clinical-stage immuno-oncology company, is developing next-generation immunotherapies that target the tumor microenvironment. A $25m debt financing commitment will support advancement of the next wave of its programmes into clinical development. Companion Medical, an innovative diabetes-focused medical device company, has developed the first and only FDA-cleared smart insulin pen and app system. A $27.5m debt financing commitment will help to drive commercial scale in support of their flagship product – InPen. Inari, an agricultural-focused biotechnology company, is developing next-generation seeds. A $45m debt financing commitment will be used to accelerate the development and commercialisation of breakthrough gene-edited crops that address the challenges of climate change and improve productivity. INSIGHT View the article What are the shifts in the sciences landscape? INSIGHT 06 JUL 2021 3 MINS Link For more information on K2 HealthVentures, click here. © Letterone Holdings S.A. 2021 © Letterone Investment Holdings S.A. 2021 +352 26 38 77 1 Email us 1 - 3 Boulevard de la Foire, L-1528 Luxembourg SITE TOOLS Terms and conditions Privacy and cookie policy Accessibility Site map Cookie settings ® LetterOne is a registered trademark of Letterone Holdings S.A. Your choice regarding cookies on this site We use cookies to optimise site functionality and give you the best possible experience. I AcceptI Do Not AcceptCookie settings